Surrogate Endpoint For Drug-Eluting Stent Trials Hotly Contested AT TCT
This article was originally published in The Gray Sheet
Executive Summary
FDA, industry and academia should pool data to determine whether late lumen loss is a viable surrogate endpoint for drug-eluting stent trials, according to CDRH Division of Cardiovascular Devices Director Bram Zuckerman, MD